Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer

Sponsor
Mayo Clinic
Status
Recruiting
ClinicalTrials.gov ID
For more information, see ClinicalTrials.gov NCT05557877
This phase II trial tests whether low-dose aspirin can affect markers of inflammation in postpartum (after childbirth) patients with benign breast disease planning to have a breast biopsy. Chronic inflammation may increase the risk of postpartum related breast cancer. Low-dose aspirin is a non-steroidal anti-inflammatory drug. Giving low-dose aspirin may affect markers of inflammation in blood and tissue and may prevent postpartum related breast cancer.
Intervention
Biospecimen Collection, Low-Dose Aspirin, Questionnaire Administration, Ultrasound-Guided Biopsy
Condition
Benign Breast Neoplasm, Breast Carcinoma, Breast Fibrocystic Change
Investigators
Kathryn J. Ruddy, M.D., Clinical Trials Referral Office, Barbara A. Pockaj, M.D., Jessica M, Tarah Ballinger, MD

See list of participating sites